Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | HTR2C | P28335 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | CCR3 | P51677 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.44 |
| ▸ | APOBEC3A | P31941 | 3/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3555505 | 0.91 | CA1 (0.50) | HTR2AHTR2CCA1CA2CA7 | |
| SCHEMBL3561910 | 0.91 | HTR2A (0.51) | HTR2AHTR2CCA1CA2CA7 | |
| SCHEMBL3563376 | 0.91 | HTR2A (0.51) | HTR2AHTR2CCA1CA2NAMPT | |
| SCHEMBL3568131 | 0.91 | CACNA1B (0.49) | HTR2AHTR2CCA1CA2CA7 | |
| SCHEMBL3562290 | 0.91 | CA1 (0.49) | HTR2AHTR2CCA1CA2CA7 | |
| SCHEMBL3565139 | 0.90 | L3MBTL1 (0.59) | CA1CA2CA7NAMPTL3MBTL1 | |
| SCHEMBL3554924 | 0.90 | L3MBTL1 (0.51) | HTR2AHTR2CCA1CA2NAMPT | |
| SCHEMBL3565549 | 0.89 | HTR2A (0.49) | HTR2AHTR2CCA1CA2CA7 | |
| SCHEMBL3560935 | 0.89 | HTR2A (0.53) | HTR2AHTR2CCA1CA2NAMPT | |
| SCHEMBL3562435 | 0.88 | L3MBTL1 (0.53) | HTR2AHTR2CNAMPTL3MBTL1APOBEC3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750161-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-07-06 | — | — | US | claimed |
| EP-1670470-B1 | PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-04-08 | — | — | EP | claimed |
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | claimed |
| US-7750161-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| EP-1670470-B1 | PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043081-A1 | Novel pyridine derivatives | P2RY4, P2RX6, P2RX4 | HTR2A 119/4885HTR2C 92/4885CA1 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.